Skip to main content

Table 1 Baseline characteristics

From: The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study

  Alfacalcidol-paricalcitol Paricalcitol-alfacalcidol
n = 26 n = 31
Age (years ± SD) 66.7 ± 10.8 67.1 ± 13.1
Gender (male/female) 17/9 17/12
Race: Caucasian 26(100%) 29(100%)
Time on dialysis (month; median (range)) 36.5 (4-236) 36.0(3-132)
Etiology of ESRD   
  Diabetes 1(4%) 5(17%)
  Nephrosclerosis 4(15%) 6(21%)
  Polycystic 5(19%) 3(10%)
  Chronic glomerulonephritis 5(19%) 4(14%)
  Chronic interstitial 2(8%) 2(7%)
  Postrenal 4(15%) 3(10%)
  Unknown 5(19%) 6(21%)
Cardiovascular history   
  Hypertension 20(77%) 22(76%)
  Diabetes 2(8%) 5(17%)
  Ischemic heart disease 9(35%) 10(34%)
  Stroke or TCI 3(12%) 7(24%)
  Heart failure 4(15%) 4(14%)
Biochemical   
  s-FGF23 (pg/ml (median (range))) 2952(95-25543) 2480(117-32650)
  p-intact PTH (pg/ml ± SD) 568(246) 523(175)
  p-calcium ion (mmol/l ± SD) 1.16(0.08) 1.15(0.08)
  p-phosphate (mmol/l ± SD) 1.50(0.23) 1.49(0.27)
  p-25hydroxyvitamin D2 + D3 (nmol/l ± SD) 43.4(24.3) 34.3(22.0)
\